Digestive Disease Week 2010. Turning Science into Medicine--part 1.

Abstract

The Digestive Disease Week 2010 conference, held in New Orleans, included topics covering new therapeutic developments in the field of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. This conference report highlights selected presentations on the novel thiopurine-based immunosuppressive agents B-0N and E-1 (both Giuliani SpA/Friedrich-Alexander-Universitaet Erlangen-Nuernberg); the investigation of ML-3403 (c-a-i-r biosciences GmbH), a p38 MAPK inhibitor for the treatment of chronic inflammatory disease; the development of ALV-003 (Alvine Pharmaceuticals Inc) for the treatment of celiac disease; efficacy studies of AST-120 in patients with irritable bowel syndrome; and a clinical trial evaluating linaclotide (Ironwood Pharmaceuticals Inc/Forest Laboratories Inc/Astellas Pharma Inc/Almirall Prodesfarma SA) withdrawal during chronic constipation therapy.

• Authors: Lisa Hodgkinson
• Journal: IDrugs : the investigational drugs journal (IDrugs) Vol. 13 Issue 7 Pg. 421-3 (Jul 2010) ISSN: 2040-3410 [Electronic] England
• PMID: 20582860 (Publication Type: Congress)

Chemical References

• Drugs, Investigational

Topics

• Animals
• Clinical Trials as Topic
• Digestive System Diseases (drug therapy)
• Drug Evaluation, Preclinical
• Drugs, Investigational (adverse effects, pharmacology, therapeutic use)
• Humans